Mitazalimab

LUND, SE / ACCESSWIRE / December 04, 2024 / Alligator Bioscience (STO:ATORX)Lund, Sweden, November 27, 2024 - Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Company was notified that the first patient has been dosed in a Phase 3 clinical trial with Shanghai Henlius Biotech, Inc. Alligator out-licensed HLX22/AC101 to AbClon, Inc. in October 2016. Abclon, Inc. subsequently sub-licensed AC101 for clinical development by Shanghai Henlius Biotech Inc."We are pleased to announce that Henlius Biotech has dosed the first patient in its Phase 3 international multi-centre clinical trial of HLX22/AC101, aiming to provide a new first-line treatment for HER2-positive advanced gastric/gastroesophageal junction cancer. This progress demonstrates Henlius' commitment to the HLX22/AC101 program. Also, this bodes well for Henlius' completion of the ongoing Phase 2 trial, which will trigger a milestone payment to Alligator," said Søren Bregenholt, CEO of Alligator Bioscience.For further information, please contact:Søren Bregenholt, CEOE-mail: [email protected]Phone: +46 (0) 46 540 82 00Johan Giléus, CFOE-mail: [email protected]Phone: +46 (0) 46 540 82 00About Alligator BioscienceAlligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer. Its portfolio includes lead drug candidate mitazalimab, for which the company reported unprecedented survival data at 18-months follow up in first-line metastatic pancreatic cancer patients in Phase 2 testing and is in preparation for Phase 3 development. The follow-on bispecific antibody ATOR-4066 is in preclinical testing. Alligator has a proprietary technology platform, comprised of two antibody libraries, ALLIGATOR-GOLD® and ALLIGATOR-FAB™, the powerful protein optimization strategy FIND® and the bispecific antibody format RUBY™, which drives rapid design and development of innovative drugs.Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden.For more information, please visit alligatorbioscience.com.AttachmentsAlligator Announces First Patient Dosed in Shanghai Henlius Biotech, Inc. Phase 3 Clinical TrialSOURCE: Alligator Bioscience

Plus, news about IPOs in Hong Kong, InventisBio and Alligator Bioscience: Bristol Myers Squibb partners with AI Proteins: The deal will focus on designing what the companies describe as “miniproteins” and developing them against targets selected by BMS. AI Proteins will get an undisclosed upfront payment and up to $400 million in milestones. — Max Gelman Terns Pharmaceuticals’ stock rallies on early-stage data for leukemia drug: The company shared early data from a Phase 1 trial assessing TERN-701 in patients with relapsed/refractory chronic myeloid leukemia. Terns CMO Emil Kuriakose said in a news release that there is a “highly encouraging” cumulative major molecular response rate of 50% at three months of treatment, adding that patients on the two lowest doses of the allosteric inhibitor saw “clinically meaningful molecular and hematologic responses.” The company now plans to start dose expansion cohorts in the first half of next year, with more data coming late in 2025. Its stock $TERN was up about 5% on Tuesday morning. — Katherine Lewin Six biotechs apply for Hong Kong listing: Since Nov. 24, at least half a dozen biotech companies have applied for listing on the Hong Kong Stock Exchange. That includes Leads Biolabs , which is partnered with Aditum Bio ; Cloudbreak Pharma , a Santen -allied ophthalmology biotech; CF PharmTech , which is developing an inhaled respiratory drug ; cell banking and cell therapy company Shanghai Cell Therapy Group ; Xuanzhu Biopharmaceutical , which is focused on cancer, digestive diseases and NASH; and immunotherapeutics maker Hanx Biopharmaceuticals . — Kyle LaHucik InventisBio touts Phase 2 data for TYK2 inhibitor in plaque psoriasis: The trial hit the primary endpoint with a “significantly greater proportion” of patients on the drug seeing a 75% or greater improvement in the Psoriasis Area and Severity Index compared to those on placebo. InventisBio also noted that 50% of patients receiving the highest dose of the drug saw a complete clearance of the skin by week 12. The complete data are set to be presented at an upcoming conference. — Katherine Lewin Alligator Bioscience announces possible layoffs, focus on pancreatic cancer drug: The Swedish company announced Monday that it may lay off about 70% of its workforce depending on negotiations with trade unions. The layoffs would impact mostly discovery and non-clinical operations. It plans to operate with 15 full-time employees going forward. While the company’s other assets are under a “strategic review,” Alligator plans to move mitazalimab into Phase 3 development for metastatic pancreatic cancer. — Katherine Lewin